<p>DiaMedica Therapeutics（纳斯达克代码：DMAC - 获取免费报告）在周二发布的报告中被华尔街 Zen 的投资分析师从 “持有” 评级下调至 “卖出” 评级。</p>
<p>其他股票研究分析师最近也对该股票发布了研究报告。Craig Hallum 将 DiaMedica Therapeutics 的目标股价从 8.00 美元上调至 11.00 美元，并在 7 月 18 日的报告中给予该股票 “买入” 评级。HC Wainwright 在 8 月 15 日的报告中重申了 “买入” 评级，并对 DiaMedica Therapeutics 的目标股价设定为 12.00 美元。最后，Lake Street Capital 在 7 月 18 日的报告中将 DiaMedica Therapeutics 的目标股价从 11.00 美元上调至 14.00 美元，并给予该股票 “买入” 评级。根据 MarketBeat.com 的数据显示，三位股票研究分析师给予该股票 “买入” 评级，公司共识评级为 “买入”，共识目标股价为 12.33 美元。</p>
<p>获取 <strong>DiaMedica Therapeutics</strong> 的提醒：</p>
<p><strong>获取我们最新的 DMAC 股票报告</strong></p>
<h2>DiaMedica Therapeutics 股票下跌 2.7%</h2>
<p>纳斯达克 DMAC 的股票在周二以 5.71 美元开盘。DiaMedica Therapeutics 的 12 个月最低价为 3.19 美元，最高价为 6.82 美元。该股票的 50 日移动平均价格为 4.70 美元，200 日移动平均价格为 4.55 美元。公司的市值为 2.9515 亿美元，市盈率为-8.28，贝塔值为 1.40。</p>
<p>DiaMedica Therapeutics（纳斯达克代码：DMAC - 获取免费报告）最后一次公布财报是在 8 月 12 日，报告显示该公司本季度每股收益为（0.18 美元），符合分析师的共识预期（0.18 美元）。整体来看，研究分析师预计 DiaMedica Therapeutics 在当前财政年度将发布-0.59 的每股收益。</p>
<h2>DiaMedica Therapeutics 的内部买卖</h2>
<p>在其他消息中，主要股东 Jan Stahlberg 在 7 月 23 日的交易中购买了 1,542,857 股该公司的股票。每股购买价格为 3.50 美元，总价值为 5,399,999.50 美元。收购完成后，该内部人士在公司持有 6,764,465 股，价值 23,675,627.50 美元。这笔交易代表了其持股比例的 29.55% 的增长。该收购在向 SEC 提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 7.30% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近对 DMAC 的持仓进行了调整。Raymond James Financial Inc.在第四季度购买了 DiaMedica Therapeutics 的新头寸，价值 83,000 美元。巴克莱银行在第四季度购买了 DiaMedica Therapeutics 的新头寸，价值 151,000 美元。Dimensional Fund Advisors LP 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 14.0%。Dimensional Fund Advisors LP 现在持有该公司 19,339 股股票，价值 105,000 美元，此前在上个季度又收购了 2,380 股。Susquehanna International Group LLP 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 269.5%。Susquehanna International Group LLP 现在持有该公司 374,845 股股票，价值 2,035,000 美元，此前在上个季度又收购了 273,395 股。最后，Northern Trust Corp 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 49.8%。Northern Trust Corp 现在持有该公司 180,192 股股票，价值 978,000 美元，此前在上个季度又收购了 59,902 股。机构投资者持有公司 10.12% 的股份。</p>
<h2>DiaMedica Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>DiaMedica Therapeutics Inc 是一家临床阶段的生物制药公司，专注于改善患有严重疾病的人的生活，重点是急性缺血性中风。其主要候选药物是 DM199，一种药理活性的重组人组织激肽酶-1 蛋白，目前正在进行急性缺血性中风的二期/三期临床试验，同时也在进行二期临床试验以治疗心肾疾病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 DiaMedica Therapeutics 更好</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>3 只具有长期顺风的医疗保健先锋</li>
<li>交易暂停的解释</li>
<li>3 只免受关税影响的零售商创下新高</li>
<li>便士股票是否适合您的投资组合？</li>
<li>随着股票接近高点，Broadcom 的第三季度报告值得关注</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 DiaMedica Therapeutics 吗？</h2>
<p>在您考虑 DiaMedica Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DiaMedica Therapeutics 并不在名单上。</p>
<p>虽然 DiaMedica Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DMAC

<p>华尔街禅将 DiaMedica Therapeutics（NASDAQ:DMAC）的评级从 “持有” 下调至 “卖出”。尽管如此，其他分析师仍给予该股票 “买入” 评级，目标价格范围在 11.00 美元至 14.00 美元之间。该股票开盘价为 5.71 美元，下跌 2.7%，市值为 2.9515 亿美元。主要股东 Jan Stahlberg 最近通过购买超过 150 万股来增加其持股比例。机构投资者持有该公司 10.12% 的股份，该公司专注于急性缺血性中风和心肾疾病的治疗</p>

<p>DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report issued on Tuesday.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics（纳斯达克代码：DMAC - 获取免费报告）在周二发布的报告中被华尔街 Zen 的投资分析师从 “持有” 评级下调至 “卖出” 评级。</p>
</div><p>Other equities research analysts have also recently issued research reports about the stock. Craig Hallum lifted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, Lake Street Capital lifted their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of &#34;Buy&#34; and a consensus price target of $12.33.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该股票发布了研究报告。Craig Hallum 将 DiaMedica Therapeutics 的目标股价从 8.00 美元上调至 11.00 美元，并在 7 月 18 日的报告中给予该股票 “买入” 评级。HC Wainwright 在 8 月 15 日的报告中重申了 “买入” 评级，并对 DiaMedica Therapeutics 的目标股价设定为 12.00 美元。最后，Lake Street Capital 在 7 月 18 日的报告中将 DiaMedica Therapeutics 的目标股价从 11.00 美元上调至 14.00 美元，并给予该股票 “买入” 评级。根据 MarketBeat.com 的数据显示，三位股票研究分析师给予该股票 “买入” 评级，公司共识评级为 “买入”，共识目标股价为 12.33 美元。</p>
</div><p>Get <strong>DiaMedica Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>DiaMedica Therapeutics</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Report on DMAC</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DMAC 股票报告</strong></p>
</div><h2>DiaMedica Therapeutics Stock Down 2.7%</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 股票下跌 2.7%</h2>
</div><p>Shares of NASDAQ DMAC opened at $5.71 on Tuesday. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $6.82. The stock's 50 day moving average price is $4.70 and its 200-day moving average price is $4.55. The company has a market capitalization of $295.15 million, a PE ratio of -8.28 and a beta of 1.40.</p>
<div class="lb-trans"><p>纳斯达克 DMAC 的股票在周二以 5.71 美元开盘。DiaMedica Therapeutics 的 12 个月最低价为 3.19 美元，最高价为 6.82 美元。该股票的 50 日移动平均价格为 4.70 美元，200 日移动平均价格为 4.55 美元。公司的市值为 2.9515 亿美元，市盈率为-8.28，贝塔值为 1.40。</p>
</div><p>DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.18). As a group, research analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics（纳斯达克代码：DMAC - 获取免费报告）最后一次公布财报是在 8 月 12 日，报告显示该公司本季度每股收益为（0.18 美元），符合分析师的共识预期（0.18 美元）。整体来看，研究分析师预计 DiaMedica Therapeutics 在当前财政年度将发布-0.59 的每股收益。</p>
</div><h2>Insider Buying and Selling at DiaMedica Therapeutics</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 的内部买卖</h2>
</div><p>In other news, major shareholder Jan Stahlberg purchased 1,542,857 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were purchased at an average price of $3.50 per share, with a total value of $5,399,999.50. Following the completion of the acquisition, the insider owned 6,764,465 shares in the company, valued at $23,675,627.50. This trade represents a 29.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，主要股东 Jan Stahlberg 在 7 月 23 日的交易中购买了 1,542,857 股该公司的股票。每股购买价格为 3.50 美元，总价值为 5,399,999.50 美元。收购完成后，该内部人士在公司持有 6,764,465 股，价值 23,675,627.50 美元。这笔交易代表了其持股比例的 29.55% 的增长。该收购在向 SEC 提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 7.30% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently made changes to their positions in DMAC. Raymond James Financial Inc. bought a new position in shares of DiaMedica Therapeutics in the fourth quarter worth $83,000. Barclays PLC purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $151,000. Dimensional Fund Advisors LP grew its position in DiaMedica Therapeutics by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after acquiring an additional 2,380 shares in the last quarter. Susquehanna International Group LLP grew its position in DiaMedica Therapeutics by 269.5% in the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after acquiring an additional 273,395 shares in the last quarter. Finally, Northern Trust Corp grew its position in DiaMedica Therapeutics by 49.8% in the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after acquiring an additional 59,902 shares in the last quarter. Institutional investors own 10.12% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近对 DMAC 的持仓进行了调整。Raymond James Financial Inc.在第四季度购买了 DiaMedica Therapeutics 的新头寸，价值 83,000 美元。巴克莱银行在第四季度购买了 DiaMedica Therapeutics 的新头寸，价值 151,000 美元。Dimensional Fund Advisors LP 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 14.0%。Dimensional Fund Advisors LP 现在持有该公司 19,339 股股票，价值 105,000 美元，此前在上个季度又收购了 2,380 股。Susquehanna International Group LLP 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 269.5%。Susquehanna International Group LLP 现在持有该公司 374,845 股股票，价值 2,035,000 美元，此前在上个季度又收购了 273,395 股。最后，Northern Trust Corp 在第四季度将其在 DiaMedica Therapeutics 的持仓增加了 49.8%。Northern Trust Corp 现在持有该公司 180,192 股股票，价值 978,000 美元，此前在上个季度又收购了 59,902 股。机构投资者持有公司 10.12% 的股份。</p>
</div><h2>DiaMedica Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>DiaMedica Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.</p>
<div class="lb-trans"><p>DiaMedica Therapeutics Inc 是一家临床阶段的生物制药公司，专注于改善患有严重疾病的人的生活，重点是急性缺血性中风。其主要候选药物是 DM199，一种药理活性的重组人组织激肽酶-1 蛋白，目前正在进行急性缺血性中风的二期/三期临床试验，同时也在进行二期临床试验以治疗心肾疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than DiaMedica Therapeutics</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
<li>Trading Halts Explained</li>
<li>3 Tariff-Proof Retailers Making New All-time Highs</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 DiaMedica Therapeutics 更好</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>3 只具有长期顺风的医疗保健先锋</li>
<li>交易暂停的解释</li>
<li>3 只免受关税影响的零售商创下新高</li>
<li>便士股票是否适合您的投资组合？</li>
<li>随着股票接近高点，Broadcom 的第三季度报告值得关注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DiaMedica Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 DiaMedica Therapeutics 吗？</h2>
</div><p>Before you consider DiaMedica Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 DiaMedica Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DiaMedica Therapeutics 并不在名单上。</p>
</div><p>While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DiaMedica Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 DiaMedica Therapeutics（NASDAQ:DMAC）的评级下调至卖出